The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Comprehensive Review of Current and Upcoming Anti-Obesity Drugs
Abstract
Obesity is among the leading causes of morbidity and mortality worldwide and its prevalence continues to increase globally. Because obesity is a chronic, complex, and heterogeneous disease influenced by genetic, developmental, biological, and environmental factors, it is necessary to approach obesity with an integrated and comprehensive treatment strategy. As it is difficult to achieve and sustain successful long-term weight loss in most patients with obesity through lifestyle modifications (e.g., diet, exercise, and behavioral therapy), pharmacological approaches to the treatment of obesity should be considered as an adjunct therapy. Currently, four drugs (orlistat, naltrexone extended-release [ER]/bupropion ER, phentermine/topiramate controlled-release, and liraglutide) can be used long-term (>12 weeks) to promote weight loss by suppressing appetite or decreasing fat absorption. Pharmacotherapy for obesity should be conducted according to a proper assessment of the clinical evidence and customized to individual patients considering the characteristics of each drug and comorbidities associated with obesity. In this review, we discuss the mechanisms of action, efficacy, and safety of these available long-term anti-obesity drugs and introduce other potential agents under investigation. Furthermore, we discuss the need for research on personalized obesity medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Children and adolescents with hypothalamic obesity have low sympathetic tone (142, 143), and thus may benefit from the stimulant-induced decrease in appetite (138, 144).”
From Management of Acquired Hypothalamic Dysfunction and the Hypothalamic Syndrome; It Is More Than Obesity (2025) · cites this paper as [143]
In the citing paper
“Reports of other types of stimulant use in individuals with hypothalamic obesity such as amphetamines have generally demonstrated weight loss or attenuation of weight gain (121, 122, 143, 146).”
From Management of Acquired Hypothalamic Dysfunction and the Hypothalamic Syndrome; It Is More Than Obesity (2025) · cites this paper as [143]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Abarca-Gómez, L., Abdeen, Z. A., Hamid, Z. A., Abu-Rmeileh, N. M., Acosta-Cazares, B., Acuin, C., Adams, R. J., Aekplakorn, W., Afsana, K., Aguilar-Salinas, C. A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32129-3 · Cited by 7,482
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Wang, G.-J., Volkow, N. D., Logan, J., Pappas, N. R., Wong, C. T., Zhu, W., Netusll, N., & Fowler, J. S. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03643-6 · Cited by 1,864
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.esgl · Cited by 1,140
Research works printed but not linked: 39
- 10.1016/s0140-6736(05)67483-1 · DOI · Paper page
- 10.2337/db08-0210 · DOI · Paper page
- 2000, WHO Consultation on Obesity
- 10.1016/S0140-6736(18)32822-8 · DOI · Paper page
- 10.1038/nrendo.2017.122 · DOI · Paper page
- 10.2165/00003495-199958040-00015 · DOI
- 10.1592/phco.20.4.270.34882 · DOI · Paper page
- Drew, 2007, Obesity management: update on orlistat, 817
- 10.1136/bmj.39406.519132.ad · DOI
- 10.1016/s0014-2999(02)01422-x · DOI · Paper page
- 10.1001/jama.293.23.2873 · DOI · Paper page
- 10.2147/dddt.s55587 · DOI · Paper page
- 10.1038/nature14260 · DOI · Paper page
- Dutia, 2012, β-Endorphin antagonizes the effects of α-MSH on food intake and body weight, 4246
- 10.1007/s40265-015-0427-5 · DOI
- 10.1016/s0140-6736(10)60888-4 · DOI · Paper page
- Apovian, 2013, A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II), 935
- 10.1038/oby.2010.147 · DOI · Paper page
- 10.1007/978-3-642-24716-3_20 · DOI
- 10.1038/oby.2011.330 · DOI · Paper page
- 10.1001/jama.2016.7602 · DOI · Paper page
- 10.1002/pds.3612 · DOI
- 10.1016/j.yend.2012.05.008 · DOI
- 10.1111/j.1467-789X.2011.00860.x · DOI
- 10.1038/nrendo.2011.77 · DOI · Paper page
- 10.1016/S0140-6736(15)00803-X · DOI · Paper page
- 10.1016/j.rbmo.2017.03.023 · DOI · Paper page
- 10.1016/s2213-8587(19)30157-3 · DOI · Paper page
- 10.1056/nejmc1611289 · DOI · Paper page
- 10.2337/dc15-0772 · DOI · Paper page
- Wang, 2014, Effect of combined naltrexone and bupropion therapy on the brain’s reactivity to food cues, 682
- 10.4158/ep161356.esgl · DOI · Paper page
- 10.1038/clpt.2013.204 · DOI · Paper page
- 10.1007/s00018-014-1650-z · DOI
- 10.1038/s41591-018-0015-9 · DOI · Paper page
- Haws, 2020, Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome, 2133
- 10.1016/s0140-6736(08)61525-1 · DOI · Paper page
- 10.1038/ijo.2010.87 · DOI
- 10.1007/s00592-017-0994-x · DOI
Cited by
The gut microbiota in obesity and weight management: microbes as friends or foe?
Van Hul, M., & Cani, P. D. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00794-0 · Cited by 318
Locatelli, J. C., Costa, J. G., Haynes, A., Naylor, L. H., Fegan, P. G., Yeap, B. B., & Green, D. J. (2024) · Diabetes Care · doi:10.2337/dci23-0100 · Cited by 152
Obesity and Eating Disorders in Children and Adolescents: The Bidirectional Link
Stabouli, S., Erdine, S., Suurorg, L., Jankauskienė, A., & Lurbe, E. (2021) · Nutrients · doi:10.3390/nu13124321 · Cited by 123
Diet-induced gut dysbiosis and inflammation: Key drivers of obesity-driven NASH
Kang, G. G., Trevaskis, N. L., Murphy, A. J., & Febbraio, M. A. (2023) · iScience · doi:10.1016/j.isci.2022.105905 · Cited by 94
Pipek, L. Z., Moraes, W. A. F., Nobetani, R. M., Cortez, V. S., Condi, A. S., Taba, J. V., Nascimento, R. F. V., Suzuki, M. O., do Nascimento, F. S., de Mattos, V. C., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-57724-5 · Cited by 80
Jungnik, A., Arrubla Martinez, J., Plum‐Mörschel, L., Kapitza, C., Lamers, D., Thamer, C., Schölch, C., Desch, M., & Hennige, A. M. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14948 · Cited by 63
Kaur, M., & Misra, S. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03646-0 · Cited by 51
van Santen, H. M., & Müller, H. L. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf025 · Cited by 21
Review on obesity management: diet, exercise and pharmacotherapy
Peri, K., & Eisenberg, M. (2024) · BMJ Public Health · doi:10.1136/bmjph-2023-000246 · Cited by 13
Pallais, J. P., Razzoli, M., Rodriguez, P., McGonigle, S., Daugherty, A., Hillman, H., Verteramo, L., Schrank, P. R., Parthiban, P., Chang, X., et al. (2026) · doi:10.64898/2026.04.18.719397 · Cited by 1
Metadata
- Authors
- Son, J. W., & Kim, S.
- Venue
- Diabetes & Metabolism Journal
- Publisher
- Korean Diabetes Association
- Published
- 2020-12-31
- Volume
- 44
- Issue
- 6
- Pages
- 802-818
- ISSN
- 2233-6079
- 2233-6087
- Cited by
- 134
- References
- 35
- Language
- en
- Licence
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.